symlin: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332	NDA	AstraZeneca Pharmaceuticals LP	0310-6615-02	2 CARTRIDGE in 1 CARTON (0310-6615-02) / 1.5 mL in 1 CARTRIDGE	2015-01-08
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332	NDA	AstraZeneca Pharmaceuticals LP	0310-6627-02	2 CARTRIDGE in 1 CARTON (0310-6627-02) / 2.7 mL in 1 CARTRIDGE	2015-01-08
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

What is SYMLIN and Its Medical Application?

SYMLIN, with the active pharmaceutical ingredient (API) pramlintide acetate, is a synthetic amylin analog used as an adjunctive therapy in the management of type 1 and type 2 diabetes mellitus. It is administered via subcutaneous injection in conjunction with mealtime insulin therapy. SYMLIN's mechanism of action involves slowing gastric emptying, suppressing glucagon secretion, and promoting satiety, which collectively helps to reduce postprandial glucose excursions and aid in weight management [1]. The drug is approved by the U.S. Food and Drug Administration (FDA) and is marketed by Amylin Pharmaceuticals, now a subsidiary of Bristol Myers Squibb.

Who Manufactures SYMLIN?

The primary manufacturer of the finished drug product SYMLIN is Amylin Pharmaceuticals, LLC, a wholly owned subsidiary of Bristol Myers Squibb. Bristol Myers Squibb oversees the commercialization and distribution of SYMLIN in various global markets. While Bristol Myers Squibb is the ultimate responsible party for the marketed product, the actual manufacturing and supply chain operations involve multiple entities.

Key Suppliers in the SYMLIN Supply Chain

The supply chain for SYMLIN involves specialized suppliers for its API, excipients, and the final drug product manufacturing. Due to the complex nature of peptide synthesis and sterile injectable formulation, these suppliers typically possess advanced capabilities.

API Manufacturing (Pramlintide Acetate)

The synthesis of pramlintide acetate is a complex multi-step process. Companies specializing in peptide synthesis are crucial to this stage. While specific contractual relationships are proprietary, companies with demonstrated expertise in large-scale peptide API manufacturing are likely partners. These include:

Lonza Group AG: Lonza is a global leader in contract development and manufacturing organization (CDMO) services, with extensive experience in complex biologics and small molecules, including peptide synthesis. Their facilities are equipped for large-scale production of APIs under stringent Good Manufacturing Practice (GMP) regulations [2].
Bachem Holding AG: Bachem is a leading custom manufacturer of peptides and oligonucleotides. They have a significant track record in producing peptides for pharmaceutical applications, from clinical trial quantities to commercial volumes [3]. Their expertise in solid-phase and liquid-phase peptide synthesis is critical.
WuXi AppTec Co., Ltd.: WuXi AppTec offers comprehensive drug discovery and development services, including API manufacturing for small molecules and peptides. Their integrated platform allows for development and scaled-up production of complex APIs [4].

The synthesis of pramlintide acetate involves precise control over amino acid coupling, purification, and lyophilization to achieve the required purity and stability for pharmaceutical use. The acetate salt form requires specific processing steps to ensure consistent drug substance quality.

Excipient Suppliers

SYMLIN is formulated as a sterile injectable solution. This requires high-purity excipients that meet pharmacopoeial standards. Key excipients typically include:

Mannitol: Used as a bulking agent in lyophilized formulations or as an osmotic agent in injectable solutions. Suppliers must adhere to USP/EP monograph standards.
- Roquette Frères: A global player in plant-based ingredients, including pharmaceutical-grade mannitol.
- Cargill, Incorporated: Offers pharmaceutical excipients, including mannitol, produced under strict quality controls.
Sodium Acetate Trihydrate: Used as a buffering agent to control pH and ensure drug stability.
- Thermo Fisher Scientific: Provides a wide range of high-purity chemicals, including sodium acetate, suitable for pharmaceutical manufacturing.
- Merck KGaA (MilliporeSigma): Offers a broad portfolio of pharmaceutical excipients, including buffering agents.
Acetic Acid (for pH adjustment): Essential for achieving and maintaining the optimal pH for pramlintide acetate stability.
- BASF SE: A major chemical producer with pharmaceutical-grade acetic acid.
- Dow Inc.: Supplies high-purity chemicals for pharmaceutical applications.
Water for Injection (WFI): The primary solvent for injectable formulations. Pharmaceutical manufacturers produce WFI on-site or procure it from specialized suppliers who meet stringent USP/EP requirements for sterility and endotoxin levels.

The quality and consistency of these excipients are paramount. Suppliers are vetted through rigorous qualification processes, including audits and testing, to ensure they meet regulatory requirements and do not introduce impurities that could affect drug safety or efficacy.

Finished Drug Product Manufacturing

The formulation and sterile filling of SYMLIN into its final dosage form (injectable solution) is a highly specialized process. Amylin Pharmaceuticals, under Bristol Myers Squibb's oversight, likely utilizes its own manufacturing facilities or contracts with specialized Contract Development and Manufacturing Organizations (CDMOs) that have aseptic processing capabilities.

Amylin Pharmaceuticals (Bristol Myers Squibb): As the brand owner, Bristol Myers Squibb maintains control over the final manufacturing steps. This can involve in-house facilities or carefully selected outsourcing partners. Their internal manufacturing sites in the U.S. have historically been involved in the production of their injectable products.
Contract Manufacturing Organizations (CMOs/CDMOs): For complex sterile injectables, companies may partner with CDMOs with expertise in lyophilization or sterile filling of peptide-based therapeutics. Examples of CDMOs with such capabilities include:
- Catalent, Inc.: A major provider of drug development and manufacturing solutions, including sterile fill-finish for biologics and complex small molecules.
- Thermo Fisher Scientific (Patheon): Offers a comprehensive range of pharmaceutical and biopharmaceutical manufacturing services, including sterile injectable fill-finish.

The sterile filling process requires advanced aseptic techniques, isolator technology, and robust environmental monitoring to prevent microbial contamination. Lyophilization, if used for SYMLIN's formulation, adds another layer of complexity, requiring specialized equipment and process validation to ensure product stability and reconstitution properties.

Regulatory Landscape and Compliance

The entire supply chain for SYMLIN is subject to stringent regulatory oversight by health authorities such as the FDA in the U.S. and the European Medicines Agency (EMA) in Europe. Key regulatory considerations include:

Good Manufacturing Practices (GMP): All manufacturing facilities, from API synthesis to finished drug product packaging, must comply with GMP regulations (21 CFR Parts 210 and 211 in the U.S.). This ensures product quality, consistency, and safety.
Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents provide detailed information about the manufacturing process, quality control, and facilities for the API. Pharmaceutical companies reference these DMFs in their drug applications.
Supplier Qualification: Pharmaceutical companies like Bristol Myers Squibb must have robust supplier qualification programs to ensure that all raw material and component suppliers meet established quality and regulatory standards. This includes audits, testing, and ongoing monitoring.
Change Control: Any changes to the manufacturing process, suppliers, or raw materials must be managed through a strict change control system and, if necessary, reported to regulatory authorities to ensure no adverse impact on product quality.
Supply Chain Security: Measures to prevent counterfeiting and ensure the integrity of the supply chain, including serialization and track-and-trace systems, are increasingly important.

Supply Chain Risks and Mitigation Strategies

The SYMLIN supply chain, like any pharmaceutical supply chain, faces inherent risks.

Potential Risks

API Supply Disruption: Dependence on a limited number of specialized peptide synthesis CDMOs can create a bottleneck. Geopolitical instability, natural disasters, or quality issues at an API supplier could halt production.
Excipient Quality Issues: Contamination or inconsistencies in excipients can lead to batch failures or necessitate product recalls. Sourcing from multiple qualified suppliers mitigates this risk.
Manufacturing Site Issues: Equipment failure, contamination events, or regulatory non-compliance at a finished drug product manufacturing site can lead to significant delays and shortages.
Logistical Challenges: Maintaining the cold chain for temperature-sensitive components or the final product during transit requires robust logistics and monitoring.
Intellectual Property and Generic Competition: While SYMLIN itself may have patent protection, the complex manufacturing process might offer a barrier to entry for generics. However, patent expiries can lead to increased competition.
Raw Material Price Volatility: The cost of specialized reagents and amino acids used in peptide synthesis can fluctuate, impacting overall production costs.

Mitigation Strategies

Dual Sourcing: Qualifying multiple suppliers for critical raw materials and APIs reduces reliance on a single source.
Robust Quality Agreements: Establishing comprehensive quality agreements with all suppliers outlines responsibilities, quality standards, and notification requirements.
Contingency Planning: Developing detailed contingency plans for potential supply disruptions, including alternative suppliers and buffer stock of critical materials.
Regular Audits and Inspections: Conducting routine audits of all manufacturing partners and suppliers to ensure ongoing compliance with GMP and quality standards.
Supply Chain Mapping: Maintaining a detailed map of the entire supply chain, including tier-2 and tier-3 suppliers, to identify potential vulnerabilities.
Inventory Management: Implementing effective inventory management systems to balance the need for buffer stock against the costs of holding inventory, particularly for temperature-sensitive materials.
Investments in Manufacturing Technology: Continuous investment in state-of-the-art manufacturing equipment and processes to improve efficiency, quality, and reduce the risk of downtime.
Regulatory Intelligence: Proactively monitoring regulatory changes and guidance to ensure ongoing compliance and anticipate future requirements.

Conclusion

The supply chain for SYMLIN is a complex network involving specialized manufacturers for its API, high-purity excipients, and sterile injectable drug product. Amylin Pharmaceuticals, under Bristol Myers Squibb, manages this chain, relying on qualified partners with expertise in peptide synthesis and aseptic manufacturing. Robust regulatory compliance, meticulous quality control, and proactive risk mitigation are essential to ensure a consistent and reliable supply of SYMLIN to patients.

Key Takeaways

SYMLIN's API, pramlintide acetate, requires specialized peptide synthesis capabilities from suppliers like Lonza, Bachem, or WuXi AppTec.
High-purity excipients, including mannitol, sodium acetate, and acetic acid, are sourced from global chemical manufacturers such as Roquette, Cargill, Thermo Fisher Scientific, and Merck KGaA.
Finished drug product manufacturing is managed by Amylin Pharmaceuticals (Bristol Myers Squibb), potentially involving their own facilities or specialized CDMOs like Catalent or Thermo Fisher Scientific (Patheon) for sterile fill-finish operations.
The entire supply chain operates under strict GMP regulations, necessitating rigorous supplier qualification, change control, and ongoing quality monitoring.
Key risks include API supply disruption, excipient quality issues, and manufacturing site failures, which are mitigated through dual sourcing, robust quality agreements, and contingency planning.

Frequently Asked Questions

What is the primary function of pramlintide acetate in SYMLIN? Pramlintide acetate slows gastric emptying, suppresses glucagon secretion, and promotes satiety to help manage postprandial glucose levels and aid in weight management in diabetic patients.
Are there any specific quality standards for excipients used in SYMLIN? Yes, excipients must meet pharmacopoeial standards, such as those outlined in the United States Pharmacopeia (USP) or European Pharmacopoeia (EP), and be of pharmaceutical grade.
What are the main regulatory bodies overseeing SYMLIN's manufacturing? The primary regulatory bodies are the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), among other national health authorities.
How does Bristol Myers Squibb ensure the quality of its SYMLIN supply chain partners? Bristol Myers Squibb employs a robust supplier qualification program that includes rigorous audits, quality agreements, and ongoing performance monitoring of its manufacturing partners and raw material suppliers.
What are the typical storage requirements for SYMLIN or its critical components? SYMLIN, as an injectable drug product, typically requires refrigeration (2°C to 8°C or 36°F to 46°F) to maintain its stability. Critical components may also have specific temperature control requirements during transit and storage.

Citations

[1] Amylin Pharmaceuticals, LLC. (n.d.). SYMLIN (pramlintide acetate) injection prescribing information. Retrieved from [Manufacturer's Website or FDA Label Database] (Note: Specific link not provided as it changes; access via FDA drug database is typical).

[2] Lonza Group AG. (n.d.). Peptides. Retrieved from lonza.com

[3] Bachem Holding AG. (n.d.). Peptide Manufacturing. Retrieved from bachem.com

[4] WuXi AppTec Co., Ltd. (n.d.). Small Molecule API Services. Retrieved from wuxiapptec.com

Suppliers and packagers for symlin

symlin

SYMLIN Drug Supply Chain Analysis